The dynamic changes in insomnia symptoms further highlight the pathological specificity of metabolic diseases: the rapid exacerbation of insomnia in the early stage is directly associated with “blood glucose anxiety during the transition period of home-based management,” while the slowed progression in the middle stage is related to hypoglycemia intervention (e.g., insulin dose adjustment) and the elevation of the central fatigue threshold (25, 26). The gene discussed is INS; the disease is insomnia.